More Receptors, More Weight Loss? The Multi-Agonist Science
Multi-Agonism
24.2% Weight Loss
Retatrutide, a triple GLP-1/GIP/glucagon agonist, produced 24.2% body weight reduction at 48 weeks in a phase 2 trial, the largest drug-induced weight loss ever recorded.
Jastreboff et al., N Engl J Med, 2023
Jastreboff et al., N Engl J Med, 2023
View as imageIn 2015, a team led by Brian Finan at the Helmholtz Diabetes Center in Munich published a paper in Nature Medicine describing a single peptide molecule that activated three metabolic hormone receptors simultaneously: GLP-1, GIP, and glucagon.[1] In obese mice, this triple agonist reduced body weight and corrected diabetes more effectively than any single- or dual-receptor agonist the researchers tested. The paper's title called it "rationally designed." The concept was deliberate: instead of blocking one pathway at a time, combine the appetite-suppressing power of GLP-1 with the metabolic fine-tuning of GIP and the energy-burning effects of glucagon into a single injectable molecule.
Eight years later, the concept reached human proof-of-concept. Retatrutide, Eli Lilly's triple GLP-1/GIP/glucagon agonist, produced 24.2% average body weight loss at 48 weeks in a phase 2 trial, a number that exceeded anything previously achieved with a drug alone.[2] The question driving the field has shifted from "can we target multiple receptors?" to "does each additional receptor actually contribute, or are we reaching the ceiling?" For a deeper look at where that ceiling might be, see The Diminishing Returns Question: Where Multi-Agonism Hits a Ceiling.
Key Takeaways
- The first rationally designed triple GLP-1/GIP/glucagon agonist reduced body weight in obese rodent models more than any single or dual agonist, establishing the multi-agonist concept (Finan et al., Nature Medicine, 2015)
- Tirzepatide (dual GIP/GLP-1 agonist) produced up to 22.5% weight loss versus 12.4% for semaglutide in the SURPASS-2 head-to-head trial (Frias et al., N Engl J Med, 2021)
- Retatrutide (triple GLP-1/GIP/glucagon agonist) achieved 24.2% weight loss at 48 weeks at the 12 mg dose, the largest weight reduction recorded for any pharmaceutical agent (Jastreboff et al., N Engl J Med, 2023)
- A systematic review of dual and triple agonists found that multi-agonist peptides achieved 15.6% to 24.2% weight loss depending on the specific molecule and dose, consistently exceeding single GLP-1 agonists (Chan et al., 2026)
- Glucagon receptor co-agonism adds a unique mechanism: increased energy expenditure through hepatic substrate oxidation and thermogenesis, complementing the appetite suppression from GLP-1 and GIP (Beji et al., 2026)
- SAR441255, a triple agonist with balanced GLP-1/GIP/glucagon activity, demonstrated significant weight loss and glycemic improvement in phase 1, validating the multi-agonist approach across multiple molecules (Bossart et al., Cell Metab, 2022)
What Each Receptor Does
To understand multi-agonism, you need to understand what happens when each receptor is activated individually.
GLP-1: The Appetite Brake
GLP-1 (glucagon-like peptide-1) is released by L-cells in the small intestine after eating. It binds receptors in the pancreas, gut, and brain. In the pancreas, it amplifies glucose-dependent insulin secretion. In the brain, it activates POMC/CART neurons in the hypothalamus and brainstem that suppress appetite. In the gut, it slows gastric emptying, making you feel full longer.[3]
Semaglutide, a pure GLP-1 receptor agonist, produces approximately 12-15% weight loss when injected weekly at 2.4 mg. This is the baseline against which multi-agonists are measured. For detailed semaglutide efficacy data, see How Much Weight Can You Lose on Semaglutide?.
GIP: The Metabolic Complement
GIP (glucose-dependent insulinotropic polypeptide) is released by K-cells in the upper small intestine. For decades, GIP was considered a poor drug target because its insulinotropic effect is blunted in type 2 diabetes. The revival of interest in GIP came from a surprising direction: when combined with GLP-1 agonism in a single molecule, GIP co-agonism produced weight loss and glycemic improvement that exceeded GLP-1 alone.[4]
The mechanism is still debated. GIP receptor activation in adipose tissue may improve lipid storage and reduce ectopic fat deposition. In the brain, GIPR signaling appears to have antiemetic effects, which could explain why tirzepatide (a dual GIP/GLP-1 agonist) causes less nausea than pure GLP-1 agonists despite producing greater weight loss. GIP may also enhance leptin sensitivity, improving the body's ability to respond to satiety signals. For a detailed comparison, see How Tirzepatide's Dual Mechanism Differs from Single GLP-1 Agonists.
Glucagon: The Energy Burner
Glucagon is traditionally viewed as the counter-regulatory hormone to insulin: it raises blood sugar by stimulating hepatic glucose output. Adding glucagon agonism to an obesity drug seems counterintuitive. But glucagon does something GLP-1 and GIP do not: it increases energy expenditure.[5]
Glucagon receptor activation drives hepatic lipid oxidation (burning fat in the liver), increases thermogenesis (generating heat from calories), promotes amino acid catabolism, and reduces hepatic lipogenesis (stopping new fat production). Beji and colleagues (2026) argued that GLP-1's primary limitation is that it reduces calorie intake without increasing calorie output, and that glucagon co-agonism fills this gap.[6]
The challenge is obvious: glucagon raises blood sugar. Any triple agonist must balance glucagon's hyperglycemic effect with enough GLP-1 and GIP activity to prevent glucose from rising. The Finan 2015 paper demonstrated that this balance is achievable in a single molecule with "equally aligned constituent activities" at all three receptors.[1]
The Progression: Single to Dual to Triple
Semaglutide: The Single-Agonist Benchmark
Semaglutide (Wegovy) targets GLP-1 receptors alone. In the STEP 1 trial, semaglutide 2.4 mg weekly produced 14.9% weight loss at 68 weeks versus 2.4% for placebo. This was considered transformative when published in 2021.
Tirzepatide: The Dual Agonist Leap
Tirzepatide (Mounjaro/Zepbound) activates both GIP and GLP-1 receptors. In SURPASS-2, tirzepatide was tested head-to-head against semaglutide in patients with type 2 diabetes. At the highest dose (15 mg), tirzepatide produced 13.1% weight loss versus 6.7% for semaglutide 1 mg, with superior HbA1c reduction.[7]
In the SURMOUNT-1 obesity trial, tirzepatide at the 15 mg dose produced 22.5% weight loss at 72 weeks.[8] This jumped from 15% to over 20% weight loss by adding GIP co-agonism. For how dual and triple agonists compare directly, see Dual vs Triple Agonist Peptides: Is More Always Better?.
Retatrutide: The Triple Agonist Record
Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously. In Jastreboff et al.'s phase 2 trial (2023), 338 adults with obesity received retatrutide at doses from 1 mg to 12 mg weekly for 48 weeks.[2]
The results by dose:
- 1 mg: 8.7% weight loss
- 4 mg (escalated): 17.1% weight loss
- 8 mg (escalated): 22.8% weight loss
- 12 mg (escalated): 24.2% weight loss
- Placebo: 2.1% weight loss
The 24.2% figure at 12 mg exceeded tirzepatide's 22.5% at a comparable timepoint. A separate analysis of retatrutide in type 2 diabetes patients (Rosenstock et al., 2023) showed similar weight loss with improved glycemic control, despite glucagon's hyperglycemic potential.[9] The GLP-1 and GIP activity successfully counterbalanced glucagon-driven glucose production. For retatrutide's mechanism in more detail, see How Retatrutide Targets Three Receptors at Once.
Does Each Receptor Actually Contribute?
The central scientific question is whether multi-agonism works through genuine receptor synergy or whether one receptor dominates and the others are passengers.
The Synergy Argument
Alavi and colleagues (2026) reviewed the evidence for multi-target incretin therapeutics and concluded that dual and triple agonists exploit complementary pathways that produce additive or synergistic effects on weight and metabolism.[10] GLP-1 reduces calorie intake. GIP improves lipid handling and may reduce nausea. Glucagon increases calorie expenditure. Each receptor adds a distinct mechanism that the others cannot replicate.
Chan et al. (2026) conducted a systematic review and meta-analysis of incretin-based dual and triple agonists in overweight or obese individuals, finding consistent dose-dependent weight loss across different multi-agonist molecules, with triple agonists producing the largest effects.[11]
The Skeptical View
The counterargument is that GLP-1 agonism is doing most of the work, and the additional receptors provide marginal benefit that could be achieved by higher GLP-1 doses. In the SURPASS-2 trial, tirzepatide was compared to semaglutide 1 mg (not the 2.4 mg obesity dose), making it difficult to determine how much of the weight loss difference came from GIP agonism versus simply more potent GLP-1 activation.[7]
Del Prato et al. (2022) noted that the relative contribution of each receptor varies by molecule, dose ratio, and patient population, and that disentangling receptor-specific effects in a multi-agonist is methodologically challenging.[3] You cannot simply subtract semaglutide's weight loss from retatrutide's and attribute the difference to GIP and glucagon.
SAR441255: Another Data Point
SAR441255 (Sanofi) is a separate triple GLP-1/GIP/glucagon agonist with "balanced" activity at all three receptors. In a phase 1 trial, it produced significant weight loss and glycemic improvement.[12] The fact that multiple structurally distinct triple agonists produce superior weight loss supports the synergy hypothesis: the effect is not unique to retatrutide's specific molecular design but appears inherent to triple-receptor activation as a strategy.
The Glucagon Paradox
The most intellectually interesting aspect of multi-agonism is the inclusion of glucagon. Elmendorf and colleagues (2026), in an IUPHAR review, traced glucagon's journey "from foe to friend" in metabolic pharmacology.[5]
For decades, glucagon was viewed strictly as a diabetes villain: it raises blood sugar, it opposes insulin, it promotes hepatic glucose output. The idea of deliberately activating glucagon receptors in patients with type 2 diabetes seemed absurd.
What changed was the recognition that glucagon's metabolic effects extend far beyond glucose. Glucagon receptor activation:
- Increases resting energy expenditure by 100-200 kcal/day through thermogenesis
- Drives hepatic fatty acid oxidation, directly reducing liver fat
- Reduces appetite independently of GLP-1 through direct central nervous system effects
- Promotes amino acid catabolism, which may contribute to lean mass turnover
The energy expenditure increase is particularly significant. GLP-1 agonists cause metabolic adaptation: as patients lose weight, their resting metabolic rate decreases, making further weight loss progressively harder. Glucagon co-agonism partially counteracts this adaptation by maintaining or increasing energy expenditure during weight loss. This is potentially why triple agonists produce weight loss curves that have not plateaued at 48 weeks in the available data.
Ganamurali and colleagues (2026) described retatrutide as a "paradigm shift in multi-hormonal pharmacotherapy," arguing that the triple-agonist approach addresses the fundamental thermodynamic limitation of appetite-only interventions: you can only reduce calorie intake so far before nausea, malnutrition, and patient noncompliance create a floor.[13] Increasing calorie expenditure simultaneously attacks the energy balance equation from both sides.
What the Data Cannot Yet Tell Us
Multi-agonism has produced the most impressive weight loss numbers in pharmaceutical history. The progression from 15% (semaglutide) to 22% (tirzepatide) to 24% (retatrutide) suggests that each additional receptor contributes meaningfully. But several critical gaps remain.
No phase 3 trial has yet compared retatrutide directly against tirzepatide at equivalent dose optimization. The phase 2 data is compelling but phase 2 trials are smaller, shorter, and designed to identify dose ranges rather than confirm superiority. Until head-to-head phase 3 results are available, the precise additional benefit of glucagon co-agonism over dual GIP/GLP-1 agonism remains estimated rather than proven.
Long-term safety data for triple agonists does not exist beyond 48 weeks. Chronic glucagon receptor activation could theoretically affect lean body mass through sustained amino acid catabolism, hepatic function through prolonged metabolic stress, or bone metabolism. These are theoretical concerns, not observed events, but the absence of long-term data means they cannot be ruled out.
The mechanism of GIP's contribution remains surprisingly unclear given tirzepatide's commercial success. Whether GIP agonism directly contributes to weight loss, primarily reduces GI side effects (allowing higher effective GLP-1 doses), or works through an entirely different pathway is still debated. For how this uncertainty shapes the broader question of multi-agonist limits, see The Diminishing Returns Question. For the alternative approach of combining separate drugs rather than building multi-agonist molecules, see Single Molecule vs Combination Therapy.
The Bottom Line
Multi-agonist peptides represent the most effective pharmaceutical approach to weight loss ever developed. The progression from single GLP-1 agonism (12-15% weight loss) to dual GIP/GLP-1 agonism (20-22%) to triple GLP-1/GIP/glucagon agonism (24%) demonstrates that targeting additional receptors produces incrementally greater effects. The evidence supports genuine mechanistic synergy: GLP-1 suppresses appetite, GIP improves metabolic efficiency and tolerability, and glucagon increases energy expenditure. Phase 3 trials and long-term safety data for triple agonists are still pending.